- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03297606
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Janet Dancey
- Phone Number: 613-533-6430
- Email: jdancey@ctg.queensu.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recruiting
- Cross Cancer Institute
-
Contact:
- Quincy Chu
- Phone Number: 780 432-8248
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- Suspended
- BCCA - Cancer Centre for the Southern Interior
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Recruiting
- BCCA - Vancouver Cancer Centre
-
Contact:
- Daniel John Renouf
- Phone Number: 672357 604 877-6000
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Recruiting
- Kingston Health Sciences Centre
-
Contact:
- Francisco Vera-Badillo
- Phone Number: 79893 613 533-6430
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- London Regional Cancer Program
-
Contact:
- Stephen Welch
- Phone Number: 519 685-8640
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- Ottawa Hospital Research Institute
-
Contact:
- John Hilton
- Phone Number: 75086 613 737-7700
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- University Health Network
-
Contact:
- Lillian Siu
- Phone Number: 416 946-2911
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- The Jewish General Hospital
-
Contact:
- Cristiano Ferrario
- Phone Number: 514 398-8307
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Recruiting
- Allan Blair Cancer Centre
-
Contact:
- Kimberly Hagel
- Phone Number: 306 766-2691
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Recruiting
- Saskatoon Cancer Centre
-
Contact:
- Sunil K. Yadav
- Phone Number: 306 655-2710
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: (screening step - non-drug specific)
- Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour (excluding primary brain tumours), multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment known to prolong life, or who has refused such treatment.
- ECOG performance status 0-2.
Patients must have normal organ function as follows:
- Absolute neutrophil count: ≥ 1.5 x 10^9/L for solid tumours; ≥ 1.0 x 10^9/L for neurologic malignancies
- Platelets ≥ 75 x 10^9/L (or ≥ 50 x 10^9/L if bone marrow involvement by myeloma or lymphoma).
- Total bilirubin ≤ 1.5 x UNL.
- AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal value unless liver metastases are present in which case they must be < 5 x ULN;
- Serum creatinine ≤ 1.5 x UNL or calculated or measured creatinine clearance ≥ 50mg/min/1.73µ^2
- Patients must have measurable disease
- Results must be available from tumour genomic or protein expression testing (if used to identify genetic variants), from one of the initiatives / groups listed in protocol Appendix VII. The test may have been performed on the primary tumour or a metastatic deposit (including bone marrow), or blood, in a diagnostic or research laboratory and must reveal a potentially actionable variant.
- Patient consent (Main Study Consent for the screening step) must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to the screening step to document their willingness to participate
- Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre or a CCTG IND site. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.
- Women/men of childbearing potential must have agreed to use a highly effective contraceptive method.
Exclusion Criteria: (screening step - non-drug specific)
- Patients with prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
- Patients with ongoing toxicity ≥ CTCAE grade 2, other than peripheral neuropathy or asymptomatic, corrected biochemical toxicities (e.g. hypothyroidism corrected by thyroid replacement), related to prior anti-tumour treatment. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.
- Patients concurrently receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g. megestrol acetate, bisphosphonates) or ongoing castration-intent therapy for prostate cancer. These medications must have been started ≥ one month prior to enrollment on this study. Patients may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific ineligibility criteria.
- Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within one month prior to screening. All patients with previously treated brain metastases must be stable (clinically and radiologically) for at least one month after completion of treatment and either off steroid treatment or only taking physiological doses of steroids prior to the screening step.
- Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure.
- Patients with known left ventricular ejection fraction (LVEF) < 40%.
- Patients with stroke (including TIA) or acute myocardial infarction within three months prior to the screening step.
- Patients with acute gastrointestinal bleeding within one month prior to the screening step.
- Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
- Lactating and nursing women
- Patients who do not meet drug-specific eligibility requirements for the drug selected by the treating physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 - Arm CLOSED, no patients recruited
VEGFR1, VEGFR2, VEGFR3
|
5mg orally twice daily
|
Experimental: Group 2 - Arm CLOSED, no patients recruited
BCR-ABL, SRC
|
500mg orally once daily
|
Experimental: Group 4 - Arm CLOSED, no patients recruited
KIT, PDGFRA, PDGFRB, ABL1
|
100mg administered orally once daily
|
Experimental: Group 5
EGFR
|
150mg orally, once daily
|
Experimental: Group 7
BRCA1, BRCA2, mutations in HRD
|
300mg taken twice daily
|
Experimental: Group 8
CDKN2A, CDK4, CCND1, SMARCA4
|
125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
|
Experimental: Group 12
BRAFV600
|
Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest |
Experimental: Group 13
PTCH1, SMO
|
150mg taken orally, once daily
|
Experimental: Group 14
ERBB2
|
300mg taken orally, twice daily
|
Experimental: Group 6 - Arm CLOSED
high mutation burden, POLE, POLD1
|
|
Experimental: Group 9 Arm CLOSED
CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
|
50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
|
Experimental: Group 11 - Arm CLOSED
ERBB2
|
Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes. |
Experimental: Group 3 - Arm CLOSED
ALK, ROS1, MET
|
250mg orally twice daily
|
Experimental: Group 10 Arm CLOSED
AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
|
25mg infused over a 30-60 minute period once a week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate defined as the number of patients with complete response or partial response
Time Frame: 4 years
|
over the total number of patients in a given cohort.
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and severity of adverse events grade >3, or of lesser grade resulting in discontinuation, delay or reduction in dose of study drug
Time Frame: 4 years
|
measured by CTCAE
|
4 years
|
Progression-free survival by disease-appropriate objective criteria
Time Frame: 4 years
|
4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Lillian Siu, Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada
- Study Chair: Daniel J Renouf, BCCA - Vancouver Cancer Centre, Vancouver BC, Canada
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Lymphoma
- Multiple Myeloma
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Immune Checkpoint Inhibitors
- MTOR Inhibitors
- Tyrosine Kinase Inhibitors
- Trastuzumab
- Olaparib
- Sunitinib
- Nivolumab
- Palbociclib
- Axitinib
- Ipilimumab
- Dasatinib
- Pertuzumab
- Vemurafenib
- Crizotinib
- Tucatinib
- Temsirolimus
- Bosutinib
Other Study ID Numbers
- PM1
- ESR-17-12831 (Other Identifier: AstraZeneca)
- CA209-9DL (Other Identifier: Bristol-Myers Squibb)
- ML39800 (Other Identifier: Hoffmann-La Roche)
- WI233446 (Other Identifier: Pfizer)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
Clinical Trials on Axitinib
-
PfizerCompletedNeoplasmsPoland, United States, Spain
-
Peking University Cancer Hospital & InstituteUnknownAdvanced Mucosal MelanomaChina
-
Acceleron Pharma Inc. (a wholly owned subsidiary...TerminatedAdvanced Renal Cell CarcinomaUnited States
-
PfizerCompletedLung Neoplasms | Carcinoma, Non-small Cell LungUnited States, Germany
-
PfizerCompletedCarcinoma, Renal CellUnited States, Spain, Japan, Germany, Czechia, Russian Federation
-
Chinese University of Hong KongCompleted
-
AkesoRecruitingRenal Cell Carcinoma | First-line TreatmentChina
-
University of Wisconsin, MadisonPfizerCompletedSolid Malignancies | Metastatic Castrate-resistant Prostate CancerUnited States
-
Spanish Cooperative Group for the Treatment of...TerminatedColorectal CarcinomaSpain
-
Assistance Publique - Hôpitaux de ParisPfizerCompletedcT2a N0NxM0 Renal TumorFrance